Enhancing rufomycin production by CRISPR/Cas9-based genome editing and promoter engineering in Streptomyces sp. MJM3502

Synthetic and Systems Biotechnology, Год журнала: 2025, Номер 10(2), С. 421 - 432

Опубликована: Янв. 18, 2025

Streptomyces sp. MJM3502 is a promising producer of rufomycins, which are class potent anti-tuberculosis lead compounds. Although the structure, activity, and mechanism main rufomycin 4/6 its analogs have been extensively studied, significant gap remains in our understanding genome sequence biosynthetic pathway MJM3502, metabolic engineering has not yet reported. This study established genetic manipulation platform for strain. Using CRISPR/Cas9-based technology to in-frame insert strong kasO∗p promoter upstream rufB rufS genes BGC, we increased production by 4.1-fold 2.8-fold, respectively. Furthermore, designing recombinant strains inserting encoding cytochrome P450 enzymes led new derivatives. These findings provide basis enhancing valuable natural compounds offer insights into generation novel active products via synthetic biology engineering.

Язык: Английский

Enhancing Rufomycin Production by CRISPR/Cas9-Based Genome Editing and Promoter Engineering in Streptomyces sp. MJM3502

Опубликована: Янв. 1, 2024

Язык: Английский